These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33190829)

  • 1. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
    Watters JM; Wright G; Smith MA; Shah B; Wright KL
    Biochem Biophys Res Commun; 2021 Jan; 534():773-779. PubMed ID: 33190829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
    Shi W; Han X; Yao J; Yang J; Shi Y
    Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
    Tiper IV; Webb TJ
    Cancer Immunol Immunother; 2016 Nov; 65(11):1411-1421. PubMed ID: 27614429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
    Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Lopez G; Pollock RE
    Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
    Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
    Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.
    Rossi LE; Avila DE; Spallanzani RG; Ziblat A; Fuertes MB; Lapyckyj L; Croci DO; Rabinovich GA; Domaica CI; Zwirner NW
    J Leukoc Biol; 2012 Feb; 91(2):321-31. PubMed ID: 22124136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
    Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
    Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages.
    Ha SD; Han CY; Reid C; Kim SO
    J Immunol; 2014 Aug; 193(3):1333-43. PubMed ID: 24973453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells.
    Dasgupta T; Antony J; Braithwaite AW; Horsfield JA
    J Biol Chem; 2016 Jun; 291(24):12761-12770. PubMed ID: 27072133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
    Lehmann M; Hoffmann MJ; Koch A; Ulrich SM; Schulz WA; Niegisch G
    J Exp Clin Cancer Res; 2014 Jul; 33(1):59. PubMed ID: 25011684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
    Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.